Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Pieris Pharma Cmn (PIRS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 245,499
  • Shares Outstanding, K 43,070
  • Annual Sales, $ 5,830 K
  • Annual Income, $ -22,800 K
  • 36-Month Beta 1.81
  • Price/Sales 41.73
  • Price/Cash Flow 0.00
  • Price/Book 13.49

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.44 +28.38%
on 06/23/17
6.20 -8.06%
on 07/12/17
+1.16 (+25.55%)
since 06/21/17
3-Month
2.28 +150.00%
on 04/25/17
6.20 -8.06%
on 07/12/17
+3.36 (+143.59%)
since 04/21/17
52-Week
1.30 +338.46%
on 11/04/16
6.20 -8.06%
on 07/12/17
+4.02 (+239.29%)
since 07/21/16

Most Recent Stories

More News
Pieris Pharmaceuticals Announces Results from 2017 Annual Meeting of Stockholders and Provides Update on Therapeutic Programs

BOSTON, MA--(Marketwired - July 05, 2017) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology...

PIRS : 5.70 (+0.88%)
Pieris Pharmaceuticals Announces Results from 2017 Annual Meeting of Stockholders and Provides Update on Therapeutic Programs

BOSTON, MA--(Marketwired - July 05, 2017) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology...

PIRS : 5.70 (+0.88%)
Technical Insights on Biotech Stocks -- Idera Pharma, Pieris Pharma, Peregrine Pharma, and Ritter Pharma

If you want a Stock Review on IDRA, PIRS, PPHM or RTTR then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. On Monday, benchmark US indices were in...

PPHM : 4.60 (-11.88%)
RTTR : 0.57 (+6.94%)
IDRA : 1.88 (-1.05%)
PIRS : 5.70 (+0.88%)
Pieris Pharmaceuticals Added to the Russell 2000(R) and Russell 3000(R) Indexes

BOSTON, MA--(Marketwired - June 27, 2017) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology...

PIRS : 5.70 (+0.88%)
Pieris Pharmaceuticals Added to the Russell 2000(R) and Russell 3000(R) Indexes

BOSTON, MA--(Marketwired - June 27, 2017) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology...

PIRS : 5.70 (+0.88%)
Pieris Pharmaceuticals Reports Financial Results for the First Quarter Ended March 31, 2017 and Provides Corporate Update

Company to Host an Investor Conference Call Tomorrow at 10:00 AM EDT

PIRS : 5.70 (+0.88%)
Pieris Pharmaceuticals Reports Financial Results for the First Quarter Ended March 31, 2017 and Provides Corporate Update

Company to Host an Investor Conference Call Tomorrow at 10:00 AM EDT

PIRS : 5.70 (+0.88%)
Pieris Pharmaceuticals to Host Conference Call on Strategic Alliance With AstraZeneca

BOSTON, MA--(Marketwired - May 03, 2017) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), today announced a strategic collaboration in respiratory disease with AstraZeneca to develop novel inhaled biologics...

PIRS : 5.70 (+0.88%)
Pieris Pharmaceuticals to Host Conference Call on Strategic Alliance With AstraZeneca

BOSTON, MA--(Marketwired - May 03, 2017) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), today announced a strategic collaboration in respiratory disease with AstraZeneca to develop novel inhaled biologics...

PIRS : 5.70 (+0.88%)
Pieris Pharmaceuticals Presents IND-enabling Data for Bispecific Immuno-Oncology Drug Candidate, PRS-343, in Poster Session at the 2017 Meeting of the American Association for Cancer Research (AACR)

BOSTON, MA--(Marketwired - April 04, 2017) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology...

PIRS : 5.70 (+0.88%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Pieris Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's drug technology consists of Anticalin(R) to treat cancer, severe asthma, anemia and other medical conditions. Pieris Pharmaceuticals, Inc. is based in Freising-Weihenstephan, Germany.

See More

Support & Resistance

2nd Resistance Point 6.01
1st Resistance Point 5.86
Last Price 5.70
1st Support Level 5.58
2nd Support Level 5.45

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.